Skip to main content

Retatrutide vs Semax

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Retatrutide

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.

Full details →

Semax

Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.

Full details →

Side-by-Side Comparison

AspectRetatrutideSemax
MechanismTriple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning.
Typical DosageClinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery.
AdministrationSubcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency.
Side EffectsSimilar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.Generally well-tolerated. May cause mild irritability or hair shedding in some users.
Best For

Key Differences

Unique to Retatrutide:

Unique to Semax:

Detailed Analysis

Retatrutide and Semax are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Retatrutide for Fat Loss. Choose Semax for Cognitive Performance.

Ready to Learn More?